Buy Back of Shares & Inter alia for discussion on: 1. Taking note on the NCLT order dated 13.09.2024 2. Consideration and Approval of Buy-back of shares as per the NCLT Order.

A.G.M.

Inter alia, to consider and approve Reconstitution of Audit Committee, Nomination & Remuneration Committee and Stakeholders Relationship Committee

Inter alia, to consider and approve:- (1) Integration and consolidation of the generics formulations business in the US market of M/s. Bayshore Pharmaceuticals LLC (wholly owned step-down subsidiary) into Unichem Pharmaceuticals (USA) Inc. (wholly owned subsidiary of Company?s subsidiary)

Inter alia, to consider and approve change among Directors including change in Chairman & Managing Director

Other business matters

Inter alia, to consider and approve the appointment of Company Secretary and Compliance Officer of the Company

Quarterly Results

Stock Split

Issue Of Warrants

Issue Of Warrants & Employees Stock Option Plan

Inter alia, to consider and approve:- (1) To consider and approve the appointment of Statutory Auditors of the company for the financial years from 2024-25 to financial year 2028-29

Inter alia, to consider and approve:- (1) The appointment of Company Secretary and Compliance Officer

Interim Dividend

Stock Split

Inter alia, to consider and approve:- 1. To confirm and approve the minutes of the previous Board Meeting dated 13th August 2024. 2. To consider and approve the allotment of 2781248 Equity Shares of face value of Rs. 10/- each fully paid up at an issue price of Rs. 32 /- per equity share (inclusive of premium of Rs. 22 /- per equity share) for an aggregate consideration of ?8,89,99,936.00 on a Preferential basis in accordance with the provisions of Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and in terms of approval accorded by the shareholders through Postal Ballot subject to In Principle Approval from BSE. 3. To consider and approve the issuance of secured, unrated, unlisted, Non-convertible Debentures (NCDs) on Private Placement Basis aggregating up to an amount of Rs. 10,00,00,000. 4.Review of Business Operations & Prospects of the Company. 5.Any other business with the permission of the chair arising out of above business and incidental and ancillary to the business.

Preferential Issue of shares & Inter alia, to transact the following business: 1. To discuss and if required, consider change of Object Clause of the Company. 2. To discuss and if required, consider change in the name of the Company. 3. To discuss and if required, approve issue of further equity shares on Preferential Allotment basis for raising funds 4. To discuss and if required, approve broad basing the Board of Directors of the Company 5. To consider any other business with the permission of the Chair.

Inter alia, to consider and approve:- (1) integration and consolidation of the generics formulations business in the US market.

inter-alia for discussion on business matters and any other item with the permission of Chair.